What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux

• https://x.com/Nellziade/status/2063269000612561273/photo/1

#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD

• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1
• https://x.com/Yuz6Yusof/status/2063272199788593497/photo/1

https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t

• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://x.com/Janetbirdope/status/2063179861397536847/photo/1
• https://twitter.com/eular_ard/status/2062509665024344391

LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK

• https://x.com/synovialjoints/status/2063217409222148317/photo/1

#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP

• https://x.com/Yuz6Yusof/status/2063217963818266828/photo/1

ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte

• https://x.com/synovialjoints/status/2063218464748179676/photo/1

First head-to-head trial to show #PsA joint outcome superiority BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%. @RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD

• https://x.com/JihaRheum/status/2063218845842571488/photo/1

Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia

• https://x.com/synovialjoints/status/2063222707315974230/photo/1

#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN

• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1
• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1

Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO

• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1

Abstr LB0004 CC312 is a CD19/CD3/CD28 tri-specific T cell engager and sustains SRI-4 responses beyond one year with rapid, deep B-cell depletion in autoimmune diseases. Not CAR-T. Not a conventional biologic. A T cell engager that redirects your own immune cells to deplete B https://t.co/rTs3Rg7BPe

• https://x.com/synovialjoints/status/2063224606043885962/photo/1

CAR-T without the CAR-T risks? AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN

• https://x.com/JihaRheum/status/2063224633923658191/photo/1

#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.